Ipamorelin

Ipamorelin is a 3rd generation GHRP behind GHRP-6 and GHRP-2. Ipamorelin has very similar characteristics of GHRP-2: does not have ghrelin’s lipogenic properties and does not promote hunger. Ipamorelin acts synergistically when applied during a Growth Hormone Releasing Hormone (GHRH) pulse or when it is administered along with a GHRH or an analog such as Sermorelin or Modified GRF 1-29 (growth releasing factor, aminos 1-29). The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH. On the other hand, Ipamorelin is similar to GHRP-6 because they both release GH at a very similar strength minus the side effects that of GHRP-6. Both GHRP-6 and GHRP-2 cause a release and an increase in cortisol and prolactin levels, however Ipamorelin only selectively releases GH at any dose. Ipamorelin shares similar functionality to Hexarelin and compared to other peptides, it is a much more stable form of ghrelin and has longer half-life periods of at least two hours long and causes secondary effect by making neurons to become excited.

Because of the way in which Ipamorelin works to stimulate the secretions relating to growth and repair, scientific study based on animal test subjects has derived a host of theorized benefits in relation to the peptide. These theorized benefits include a strengthening of bone mass, an improvement in skin tone, a boost in the burning of adipose tissue, a strengthening of connective tissue, and a strengthening and rejuvenation of joints. Due to the nature of these theorized benefits, some scientific studies have been able to determine that the peptide could play a vital role in the overall slowing down of the aging process.